Brian Piekos - 01 Feb 2024 Form 4 Insider Report for Elicio Therapeutics, Inc. (ELTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: ELTX
Reported as of: 01 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Feb 2024, 06:01:51 UTC
Prior SEC filing: 05 Jun 2023
Next SEC filing: 11 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/Brian Piekos

Key filing fact

Brian Piekos filed Form 4 for Elicio Therapeutics, Inc. (ELTX) on 05 Feb 2024.

Key facts

This page summarizes Brian Piekos's Form 4 filing for Elicio Therapeutics, Inc. (ELTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Feb 2024, 06:01.

Change

Previous filing in this sequence was filed on 05 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +43,225
Change %
Price: $0.000000
Shares after: 43,225
Date: 01 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 43,225
Exercise price: $4.50
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Twenty five percent (25%) of the stock options vest on February 1, 2025, the one-year anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.